Intercept Pharmaceuticals, 3.5% 15feb2026, USD (Conv.) (FIGI BBG01239DFQ5, WKN A3K8SU)
国内債券, 転換社債, トレース適格, Senior Secured
国内債券, 転換社債, トレース適格, Senior Secured
|
Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC), non-alcoholic fatty liver disease ...
Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC), non-alcoholic fatty liver disease (or non-alcoholic steatohepatitis, NASH), cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea.
|
|
|
|
|
|
|
|
|
|
|
最も包括的なデータベースを探索
1 000 000
債券
80 234
株
161 443
ETF&投資信託
70 000
インデックス
最も効率的な方法でポートフォリオを追跡
| 2023 | |
| 2022 | |
| 2021 | |
| 2020 | |
| 2019 | |
| 2018 | |
| 2017 | |
| 2016 | |
| 2015 | |
| 2014 | |